F. Rodeghiero

发表

How to estimate bleeding risk in mild bleeding disorders

A. Tosetto, F. Rodeghiero, G. Castaman, 2007, Journal of thrombosis and haemostasis : JTH.

F. Rodeghiero, A. Federici, D. Lillicrap, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience.

F. Mandelli, G. Leone, G. Avvisati, 2007, Blood.

Evaluation of lymphocytes inactivation by extracorporeal photopheresis using tetrazolium salt based-assay.

F. Rodeghiero, K. Chieregato, A. Alghisi, 2015, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Reduced von Willebrand factor secretion is associated with loss of Weibel–Palade body formation

F. Rodeghiero, G. Castaman, R. Schneppenheim, 2012, Journal of thrombosis and haemostasis : JTH.

Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype

F. Rodeghiero, G. Castaman, R. Schneppenheim, 2010, Journal of thrombosis and haemostasis : JTH.

Von Willebrand Disease Type 2M “Vicenza” in Italian and German Patients: Identification of the First Candidate Mutation (G3864A; R1205H) in 8 Families

P. Mannucci, P. Mannucci, F. Rodeghiero, 2000, Thrombosis and Haemostasis.

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

F. Ferrara, A. Cuneo, G. Pizzolo, 2006, Blood.

Old and new prognostic factors in acute myeloid leukemia with deranged core‐binding factor beta

G. Martinelli, F. Ferrara, G. Pizzolo, 2013, American journal of hematology.

VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.

J. Goudemand, J. Eikenboom, J. Batlle, 2013, Blood.

THROMBOSIS AND HEMOSTASIS VWF propeptide and ratios between VWF , VWF propeptide , and FVIII in the characterization of type 1 von Willebrand disease

J. Goudemand, J. Eikenboom, J. Batlle, 2013 .

Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM‐1VWD study

J. Goudemand, S. Lethagen, J. Eikenboom, 2009, Journal of Thrombosis and Haemostasis.

Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

J. Goudemand, S. Lethagen, J. Eikenboom, 2008, Blood.

Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD)

J. Goudemand, S. Lethagen, J. Eikenboom, 2008, Journal of thrombosis and haemostasis : JTH.

Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).

J. Goudemand, C. Halldén, S. Lethagen, 2007, Blood.

Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD

J. Goudemand, S. Lethagen, J. Eikenboom, 2006, Journal of thrombosis and haemostasis : JTH.

Epidemiological investigation of the prevalence of von Willebrand's disease.

F Rodeghiero, F. Rodeghiero, G. Castaman, 1987, Blood.

The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases

H Tunstall-Pedoe, V Tikhonoff, A Hofman, 2007, European Journal of Epidemiology.

Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.

H Tunstall-Pedoe, Simon G Thompson, John Danesh, 2005, JAMA.

ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders

B. Coller, A. Tosetto, P. James, 2010, Journal of thrombosis and haemostasis : JTH.

Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact.

F. Rodeghiero, F. Elice, 2010, Thrombosis research.

Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation

N. Bolli, B. Falini, I. Nicoletti, 2007, Leukemia.

Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia.

T. Barbui, G. Rossi, F. Rodeghiero, 1996, Leukemia & lymphoma.

Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists

F. Rodeghiero, G. Carli, 2017, Annals of Hematology.

Relevance of quantitative assessment of bleeding in haemorrhagic disorders

A. Tosetto, P. James, F. Rodeghiero, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

M. Cazzola, M. Baccarani, T. Barbui, 2012, American journal of hematology.

High levels of histidine-rich glycoprotein and thrombotic diathesis. Report of two unrelated families.

F. Rodeghiero, G. Castaman, M. Ruggeri, 1993, Thrombosis research.

Leukocytosis as an important risk factor for arterial thrombosis in WHO‐defined early/prefibrotic myelofibrosis: An international study of 264 patients

T. Barbui, A. Vannucchi, F. Passamonti, 2012, American journal of hematology.

Characterization of a novel bleeding disorder with isolated prolonged bleeding time and deficiency of platelet microvesicle generation

F. Rodeghiero, G. Castaman, L. Yu-feng, 1997, British journal of haematology.

Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study

A. Tosetto, S. Lethagen, J. Eikenboom, 2006, Journal of thrombosis and haemostasis : JTH.

Thrombopoietin receptor agonists in hereditary thrombocytopenias

F. Rodeghiero, C. Balduini, A. Pecci, 2018, Journal of thrombosis and haemostasis : JTH.

Production of human platelet lysate by use of ultrasound for ex vivo expansion of human bone marrow-derived mesenchymal stromal cells.

F. Rodeghiero, K. Chieregato, A. Alghisi, 2013, Cytotherapy.

The epidemiology of inherited thrombophilia: the VITA Project. Vicenza Thrombophilia and Atherosclerosis Project.

A. Tosetto, F. Rodeghiero, 1997, Thrombosis and haemostasis.

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

T. Barbui, G. Leone, P. Guglielmelli, 2008, Haematologica.

Side effects of anti-angiogenic drugs.

F. Rodeghiero, F. Elice, 2012, Thrombosis research.

Vascular complications of endothelium targeting therapies

F. Rodeghiero, F. Elice, 2009 .

Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long‐term cognitive functioning

M. Vignetti, M. Luppi, F. Cottone, 2020, British journal of haematology.

thrombocythemia: a retrospective survey Post-surgery outcomes in patients with polycythemia vera and essential

T. Barbui, A. Vannucchi, A. Tosetto, 2013 .

Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey.

T. Barbui, A. Vannucchi, A. Tosetto, 2008, Blood.

Mortality from myelodysplastic syndromes: A multiple causes of death approach

F. Rodeghiero, U. Fedeli, E. Schievano, 2014, American journal of hematology.

Treatment practices in adults with chronic immune thrombocytopenia – a European perspective

F. Rodeghiero, M. Michel, D. Provan, 2010, European journal of haematology.

The VITA Project: Phenotypic Resistance to Activated Protein C and FV Leiden Mutation in the General Population

A. Tosetto, E. Missiaglia, F. Rodeghiero, 1997, Thrombosis and Haemostasis.

based on the analysis of 68 cases The spectrum of Evans syndrome in adults: new insight into the disease

J. Piette, E. Andrès, P. Bierling, 2012 .

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

J. George, J. Bussel, V. Blanchette, 2009, Blood.

The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases.

J. Piette, E. Andrès, P. Bierling, 2009, Blood.

an international working group immune thrombocytopenic purpura of adults and children: report from Standardization of terminology, definitions and outcome criteria in

J. George, J. Bussel, D. Cines, 2009 .

Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

T. Barbui, G. Barosi, F. Rodeghiero, 2004, Haematologica.

Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years.

V. De Stefano, C. Santoro, F. Rodeghiero, 2019, Thrombosis research.

Recurrent Venous Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia

T. Barbui, G. Leone, P. Guglielmelli, 2007 .

Severe spontaneous arterial thrombotic manifestations in patients with inherited hypo‐ and afibrinogenemia

F. Rodeghiero, G. Castaman, E. Bonoldi, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years

M. Baccarani, M. Björkholm, E. Morra, 2013, Haematologica.

Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis.

K. W. Davidson, J. Gallacher, J. Danesh, 2012, International journal of epidemiology.

Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery

T. Barbui, A. Falanga, R. Consonni, 1993, British journal of haematology.

Diagnosing type 1 von Willebrand disease: good for patient's health or for doctor's prestige?

F. Rodeghiero, 2014, Journal of thrombosis and haemostasis : JTH.

Replacement Therapy with Virus—Inactivated Plasma Concentrates in von Willebrand Disease

P. Mannucci, F. Rodeghiero, G. Castaman, 1992, Vox sanguinis.

Mutations in the thrombomodulin gene are rare in patients with severe thrombophilia

F. Rodeghiero, G. Castaman, E. Faioni, 2002, British journal of haematology.

Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia

H. Gisslinger, A. Tosetto, E. Missiaglia, 2002, American journal of hematology.

Economic assessment of eltrombopag in the treatment of thrombocytopenia

E. Giannini, F. Rodeghiero, M. Ruggeri, 2015, Expert review of pharmacoeconomics & outcomes research.

Von Willebrand disease

F. Rodeghiero, 2014, Hematology.

The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease.

P. Mannucci, M. Morfini, P. Bucciarelli, 2014, Blood.

Von Willebrand disease: pathogenesis and management.

F. Rodeghiero, 2013, Thrombosis research.

Clinical, Laboratory, and Molecular Markers of Type 1 von Willebrand Disease

F. Rodeghiero, D. Lillicrap, I. Peake, 2011 .

Advances in the diagnosis and management of type 1 von Willebrand disease

F. Rodeghiero, G. Castaman, 2011, Expert review of hematology.

von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels

D. Hampshire, J. Goudemand, J. Eikenboom, 2010, Journal of thrombosis and haemostasis : JTH.

Optimizing treatment of von Willebrand disease by using phenotypic and molecular data.

A. Tosetto, F. Rodeghiero, G. Castaman, 2009, Hematology. American Society of Hematology. Education Program.

How I treat How I treat von Willebrand disease

A. Tosetto, F. Rodeghiero, G. Castaman, 2009 .

How I treat von Willebrand disease.

A. Tosetto, F. Rodeghiero, G. Castaman, 2009, Blood.

Hyper‐responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra‐platelet von Willebrand factor

P. Mannucci, F. Rodeghiero, G. Castaman, 1988, European journal of haematology.

Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease

P. Mannucci, F. Rodeghiero, G. Castaman, 1995, British journal of haematology.

The elusive pathogenesis of von Willebrand disease Vicenza.

P. Mannucci, F. Rodeghiero, G. Castaman, 2002, Blood.

von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers.

F. Rodeghiero, G. Castaman, P. Mannucci, 1988, Blood.

Prospective Multicenter Study on Subcutaneous Concentrated Desmopressin for Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A

P. Mannucci, F. Rodeghiero, G. Castaman, 1996, Thrombosis and Haemostasis.

F. Rodeghiero, C. Mazurier, 2001, Thrombosis and Haemostasis.

A novel family with recessive von Willebrand disease due to compound heterozygosity for a splice site mutation and a missense mutation in the von Willebrand factor gene.

J. Eikenboom, F. Rodeghiero, G. Castaman, 2002, Thrombosis research.

The aspirin tolerance test in von Willebrand's disease.

T. Barbui, F. Rodeghiero, E. Dini, 1977, Thrombosis and haemostasis.

Characterization of the Genetic Defects in Recessive Type 1 and Type 3 von Willebrand Disease Patients of Italian Origin

R. Bertina, J. Eikenboom, F. Rodeghiero, 1998, Thrombosis and Haemostasis.

Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A.

F. Rodeghiero, G. Castaman, M. Ruggeri, 1989, Blood.

Autosomal dominant type 1 von Willebrand disease due to G3639T mutation (C1130F) in exon 26 of von Willebrand factor gene: description of five Italian families and evidence for a founder effect

J. Eikenboom, E. Missiaglia, F. Rodeghiero, 2000, British journal of haematology.

Inconsistency of Association between Type 1 von Willebrand Disease Phenotype and Genotype in Families Identified in an Epidemiological Investigation

R. Bertina, J. Eikenboom, F. Rodeghiero, 1999, Thrombosis and Haemostasis.

Acquired von Willebrand Syndrome: Data from an International Registry

P. V. van Genderen, H. Mohri, P. Bucciarelli, 2000, Thrombosis and Haemostasis.

A novel candidate mutation (Arg611→ His) in type I‘platelet discordant’von Willebrand's disease with desmopressin‐induced thrombocytopenia

P. Reitsma, J. Eikenboom, F. Rodeghiero, 1995, British journal of haematology.

Provisional criteria for the diagnosis of VWD type 1: on behalf of the ISTH SSC Subcommittee on von Willebrand Factor

F. Rodeghiero, J. Sadler, 2005, Journal of thrombosis and haemostasis : JTH.

Pharmacokinetics of Monoclonally-Purified and Recombinant Factor VIII in Patients with Severe von Willebrand Disease

P. Mannucci, M. Morfini, F. Rodeghiero, 1993, Thrombosis and Haemostasis.

Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease.

F. Rodeghiero, G. Castaman, N. Ciavarella, 1989, Blood.

Desmopressin and type II B von Willebrand disease

F. Rodeghiero, G. Castaman, 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

Two dimensional immunoelectrophoresis of antithrombin III during disseminated intravascular coagulation in acute leukemia.

T. Barbui, F. Rodeghiero, 1978, Thrombosis research.

Mutation pattern in clinically asymptomatic coagulation factor VII deficiency

M. Pinotti, F. Bernardi, M. Pinotti, 1996, Human mutation.

Multivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine‐induced killer cells

F. Rodeghiero, M. Stocchero, K. Chieregato, 2013, Cytometry. Part B, Clinical cytometry.

Effect of platelet lysate on the functional and molecular characteristics of mesenchymal stem cells isolated from adipose tissue.

F. Rodeghiero, C. Visco, K. Chieregato, 2011, Current stem cell research & therapy.

Acute Leukemias Prognostic significance of CD56 antigen expression in acute myeloid leukemia

F. Rodeghiero, R. Sartori, R. Zambello, 2002 .

Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V

F. Bernardi, E. Missiaglia, F. Rodeghiero, 1997, British journal of haematology.

Clinical Manifestations and Management of Inherited Thrombophilia: Retrospective Analysis and Follow-up after Diagnosis of 238 Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S

T. Barbui, G. Leone, P. Mannucci, 1994, Thrombosis and Haemostasis.

Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long‐term follow‐up of a randomized clinical trial

T. Barbui, F. Rodeghiero, G. Finazzi, 2000, British journal of haematology.

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.

T. Barbui, F. Rodeghiero, G. Finazzi, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phenotypic APC Resistance in Carriers of the A20210 Prothrombin Mutation Is Associated with an Increased Risk of Venous Thrombosis

A. Tosetto, F. Rodeghiero, G. Castaman, 2001, Thrombosis and Haemostasis.

Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report

P. Noris, A. Srivastava, V. Blanchette, 2019, HemaSphere.

Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET).

B. Cosmi, L. Ansaloni, M. Marietta, 2009, Thrombosis research.

Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study.

S. Mundell, S. Watson, F. Rodeghiero, 2009, Blood.

Chronic immune thrombocytopenic purpura

F. Rodeghiero, M. Ruggeri, 2009, Hämostaseologie.

Short‐ and long‐term risks of splenectomy for benign haematological disorders: should we revisit the indications?

F. Rodeghiero, M. Ruggeri, 2012, British journal of haematology.

Evidence and Clinical Judgment: Vena cava filters

W. Ageno, F. Dentali, G. Palareti, 2014, Thrombosis and Haemostasis.

Clinical usefulness of desmopressin for prevention of surgical bleeding in patients with symptomatic heterozygous factor XI deficiency

F. Rodeghiero, G. Castaman, M. Ruggeri, 1996, British journal of haematology.

Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance

A. Tosetto, F. Rodeghiero, G. Castaman, 2011, Thrombosis and Haemostasis.

Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients.

T. Barbui, F. Mandelli, G. Avvisati, 1990, Blood.

Hepatocellular carcinoma in hemophilia

M. Colombo, P. Mannucci, D. Brettler, 1991, American journal of hematology.

Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A

P. Mannucci, E. Santagostino, A. Tosetto, 2009, Journal of thrombosis and haemostasis : JTH.

Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.

A. Tosetto, J. Goudemand, S. Lethagen, 2008, Blood.

Epidemiology of hemophilia and of HIV infection in Italy. GICC. Gruppo Italiano Coagulopatie Congenite.

N. Binkin, F. Rodeghiero, F. Chiarotti, 1994, Journal of clinical epidemiology.

Idiopathic thrombocytopenic purpura: an old disease revisited in the era of evidence-based medicine.

F. Rodeghiero, 2003, Haematologica.

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

M. Cazzola, T. Barbui, D. Larson, 2013, Leukemia.

Platelet Cut-Off For Anticoagulant Therapy In Cancer Patients With Venous Thromboembolism and Thrombocytopenia: An Expert Opinion Based On RAND/UCLA Appropriateness Method (RAM)

A. Tosetto, A. Falanga, M. Marietta, 2013 .

Obstetric complications and pregnancy-related venous thromboembolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation

G. Tiscia, M. Margaglione, E. Grandone, 2012, Thrombosis and Haemostasis.

Low prevalence of thrombophilia coagulation defects in patients with deep vein thrombosis of the upper limbs

A. Tosetto, F. Rodeghiero, G. Castaman, 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A hit to current “hit” wisdom: A century later, it's time for a change

F. Rodeghiero, 2017, American journal of hematology.

Updated international consensus report on the investigation and management of primary immune thrombocytopenia.

J. Bussel, B. Chong, Y. Tomiyama, 2019, Blood advances.

A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP

F. Rodeghiero, 2018, British journal of haematology.

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria

T. Barbui, A. Vannucchi, F. Passamonti, 2012, Leukemia.

Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders.

F. Rodeghiero, L. Trentin, R. Zambello, 1996, Blood.

Fulminant sepsis in adults splenectomized for Hodgkin's disease.

F. Rodeghiero, G. Castaman, M. Frezzato, 1993, Haematologica.

Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study

M. Cazzola, T. Barbui, A. Vannucchi, 2011 .

A Phase II Study of the HDAC Inhibitor Givinostat In Combination with Hydroxyurea In Patients with Polycythemia Vera Resistant to Hydroxyurea Monotherapy

T. Barbui, V. Martinelli, G. Barosi, 2011 .

Immunoelectrophoretic evidence of a thrombin‐induced abnormality in a new variant of hereditary dysfunctional antithrombin III (AT III ‘Vicenza’)

T. Barbui, F. Rodeghiero, G. Finazzi, 1983, British journal of haematology.

Multimeric pattern of plasma and platelet von willebrand factor is normal in uremic patients

P. Mannucci, F. Rodeghiero, G. Castaman, 1993, American journal of hematology.

Inherited abnormalities of blood coagulation in juvenile stroke. A case‐control study

A. Tosetto, F. Rodeghiero, G. Castaman, 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A comparative evaluation of gene transfer into blood cells using the same retroviral backbone for independent expression of the EGFP and deltaLNGFR marker genes.

F. Rodeghiero, R. Bonaguro, D. Madeo, 2000, Haematologica.

Treatment of acute lymphoblastic leukemia in adults

T. Barbui, T. Chisesi, F. Rodeghiero, 1985, Hematological oncology.

Thrombopoietin receptor agonists: ten years later

J. Bussel, F. Rodeghiero, B. Godeau, 2019, Haematologica.

Type I factor XIII deficiency is caused by a genetic defect of its b subunit: insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain.

A. Tosetto, A. Girolami, F. Rodeghiero, 1996, Blood.

Clinical pharmacokinetics of a placenta‐derived factor XIII concentrate in type I and type II factor XIII deficiency

A. Tosetto, F. Rodeghiero, G. Castaman, 1991, American journal of hematology.

Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature

S. Fortuna, F. Rodeghiero, M. Ruggeri, 2008, Haematologica.

an Italian retrospective study mutations in core binding factor leukemias: c-KIT Prognostic impact of

G. Pizzolo, G. Nadali, M. Nichelatti, 2012 .

High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia.

T. Lister, A. Rohatiner, T. Barbui, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Subunit A of Factor XIII Regulates Subunit B Plasma Concentration

T. Barbui, F. Rodeghiero, M. Morbin, 1981, Thrombosis and Haemostasis.

Bleeders, bleeding rates, and bleeding score

A. Tosetto, F. Rodeghiero, G. Castaman, 2013, Journal of thrombosis and haemostasis : JTH.

Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide

A. Palumbo, M. Boccadoro, J. Zeldis, 2006, Journal of thrombosis and haemostasis : JTH.

Thalidomide and Thrombosis

F. Rodeghiero, F. Elice, 2003, Pathophysiology of Haemostasis and Thrombosis.

Twenty years experience with treatment of idiopathic thrombocytopenic purpura in a single department: results in 490 cases.

F. Rodeghiero, C. Schiavotto, 1993, Haematologica.

Effectiveness of lenalidomide in a patient with refractory anemia with ring sideroblasts and thrombocytosis with JAK2 (V617F) mutation

I. Nichele, F. Rodeghiero, M. Ruggeri, 2015, American journal of hematology.

P-310 Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Results of a prospective, randomized trial

M. Voso, R. Latagliata, F. Morabito, 2013 .

Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia

A. Neri, G. Pizzolo, M. Scupoli, 2013, American journal of hematology.

Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group.

T. Barbui, M. Vignetti, F. Mandelli, 2004 .

First‐line therapies for immune thrombocytopenic purpura: re‐evaluating the need to treat

F. Rodeghiero, 2008, European journal of haematology. Supplementum.

Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists.

F. Rodeghiero, M. Ruggeri, 2015, Seminars in hematology.

Romiplostim or standard of care in patients with immune thrombocytopenia.

B. Chong, F. Rodeghiero, I. Pabinger, 2010, The New England journal of medicine.

Is splenectomy still the gold standard for the treatment of chronic ITP?

F. Rodeghiero, M. Ruggeri, 2008, American journal of hematology.

Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials

D. Cines, J. Viallard, A. Giagounidis, 2013, European journal of haematology.

Is ITP a thrombophilic disorder?

F. Rodeghiero, 2016, American journal of hematology.

Ifosfamide in Hematological Malignancies of Adults

F. Rodeghiero, F. Elice, 2003, Oncology.

Thrombosis during Pregnancy and Surgery in Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S

T. Barbui, G. Leone, P. Mannucci, 1994, Thrombosis and Haemostasis.

Loss of the JAK2 intramolecular auto‐inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis

A. Giorgetti, F. Rodeghiero, M. Ruggeri, 2008, British journal of haematology.

Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: Report of a new mutation

F. Rodeghiero, M. Ruggeri, E. Albiero, 2009, American journal of hematology.

Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia

T. Barbui, G. Leone, P. Guglielmelli, 2009, American journal of hematology.

Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation

T. Barbui, G. Leone, P. Guglielmelli, 2010, Annals of Hematology.

Diagnosing type 1 von Willebrand disease: good for patient's health or for doctor's prestige?: reply

F. Rodeghiero, 2014, Journal of thrombosis and haemostasis : JTH.

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia

T. Barbui, A. Vannucchi, F. Passamonti, 2015, Blood Cancer Journal.

Salvage Therapy for Resistant or Relapsing Acute Lymphoblastic Leukemia (ALL) after Idarubicin-Based Induction

T. Barbui, F. Rodeghiero, R. Sartori, 2003 .

Rabbit antithymocyte globulin (r‐ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy

F. Rodeghiero, A. Bacigalupo, C. Dufour, 1999, British journal of haematology.

Multiplex Amplification and Fluorimetric Detection of Short Tandem Repeats for Mixed Chimerism After Bone Marrow Transplant

F. Rodeghiero, G. Castaman, R. Raimondi, 2003, Leukemia & lymphoma.

Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?

A. Neri, F. Maura, A. Cortelezzi, 2014, Leukemia & lymphoma.

Validated questionnaire for the identification of previous personal or familial venous thromboembolism.

A. Tosetto, F. Rodeghiero, M. Frezzato, 1996, American journal of epidemiology.

Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis

A. Tosetto, F. Rodeghiero, G. Castaman, 1999, British journal of haematology.

The role of platelet von Willebrand factor in platelet adhesion and thrombus formation: a study of 34 patients with various subtypes of type I von Willebrand disease

P. Mannucci, C. Rothschild, F. Rodeghiero, 1994, British journal of haematology.

Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma.

A. Piccin, F. Rodeghiero, G. Castaman, 2002, Haematologica.

Association of factor V deficiency with factor V HR2.

F. Rodeghiero, G. Castaman, E. Faioni, 2004, Haematologica.

The A20210 allele in the prothrombin gene enhances the risk of venous thrombosis in carriers of inherited protein S deficiency

A. Tosetto, F. Rodeghiero, G. Castaman, 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Risk Factors for Thromboembolism

A. Tosetto, F. Rodeghiero, 1999 .

Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation

A. Tosetto, F. Rodeghiero, G. Castaman, 1998, American journal of hematology.

The VITA Project: Prothrombin G20210A Mutation and Venous Thromboembolism in the General Population

A. Tosetto, E. Missiaglia, F. Rodeghiero, 1999, Thrombosis and Haemostasis.

Autosomal recessive von Willebrand disease associated with compound heterozygosity for a novel nonsense mutation (2908 del C) and the missense mutation C2362F: Definite evidence for the non‐penetrance of the C2362F mutation

J. Eikenboom, F. Rodeghiero, G. Castaman, 2007, American journal of hematology.

Epidermal growth factor, basic fibroblast growth factor and platelet-derived growth factor-bb can substitute for fetal bovine serum and compete with human platelet-rich plasma in the ex vivo expansion of mesenchymal stromal cells derived from adipose tissue.

F. Rodeghiero, K. Chieregato, G. Astori, 2011, Cytotherapy.

A bleeding disorder characterised by isolated deficiency of platelet microvesicle generation

F. Rodeghiero, G. Castaman, L. Yu-feng, 1996, The Lancet.

Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif

N. Bolli, B. Falini, I. Nicoletti, 2007, Leukemia.

Treatment of 49 Unrandomized Patients with Advanced Hodgkin's Disease

T. Chisesi, F. Pozza, F. Rodeghiero, 1983, Tumori.

Immune thrombocytopenia in lymphoproliferative disorders.

F. Rodeghiero, C. Visco, 2009, Hematology/oncology clinics of North America.

Immune Thrombocyt openia in Lymphoproliferative Disorders

F. Rodeghiero, 2009 .

Author ' s personal copy ImmuneThrombocytopenia in Lymphoproliferative

F. Rodeghiero, CarloVisco, 2009 .

von Willebrand disease: still an intriguing disorder in the era of molecular medicine

F. Rodeghiero, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Congenital von Willebrand disease type I: definition, phenotypes, clinical and laboratory assessment.

F. Rodeghiero, G. Castaman, G. Castaman, 2001, Best practice & research. Clinical haematology.

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.

T. Barbui, A. Vannucchi, F. Passamonti, 2011, Blood.

Identical IGHV‐D‐J gene rearrangement may precede the clinical onset of chronic lymphocytic leukemia by several years

F. Rodeghiero, D. Madeo, I. Giaretta, 2010, American journal of hematology.

Detection of identical T‐cell clonotype expansions in both the donor and recipient after allogeneic bone marrow transplantation

F. Rodeghiero, A. Bacigalupo, L. Trentin, 1999, British journal of haematology.

Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease

Alicja R. Rudnicka, Yoav Ben-Shlomo, Simon G. Thompson, 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

von Willebrand Disease "Vicenza" With Larger-Than-Normal (Supranormal) von

P. Mannucci, F. Rodeghiero, G. Castaman, 2016 .

von Willebrand factor multimers von Willebrand disease "Vicenza" with larger-than-normal (supranormal)

F. Rodeghiero, G. Castaman, P. Mannucci, 2011 .

In vivo experiments indicate that relatively high platelet deposition in von Willebrand's disease 'Vicenza' is caused by normal platelet-VWF levels rather than by high VWF-multimers in plasma.

J. Sixma, P. Mannucci, P. D. de Groot, 1992, Thrombosis research.

Eltrombopag second‐line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off‐treatment: results of a phase II, multicentre, prospective study

U. Dianzani, R. Fanin, M. Vignetti, 2021, British journal of haematology.

Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Italian Cooperative Group for TTP.

C. Porta, E. Ascari, F. Rodeghiero, 1995, Haematologica.

High-throughput immunophenotypic characterization of bone marrow- and cord blood-derived mesenchymal stromal cells reveals common and differentially expressed markers: identification of angiotensin-converting enzyme (CD143) as a marker differentially expressed between adult and perinatal tissue sour

F. Rodeghiero, G. Rotta, M. Ruggeri, 2018, Stem Cell Research & Therapy.

Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use

F. Rodeghiero, M. Ruggeri, O. Perbellini, 2017, Stem Cell Research & Therapy.

Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future

F. Rodeghiero, R. Schäfer, F. Bambi, 2016, Stem Cell Research & Therapy.

The von Willebrand factor

F. Rodeghiero, G. Castaman, 1990, La Ricerca in clinica e in laboratorio.

Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease.

P. Mannucci, F. Rodeghiero, G. Castaman, 1991, Blood reviews.

Progressive multifocal leuconcephalopathy and autoimmune haemolytic anemia in chronic lymphocytic leukaemia: more than a fortuitous combination?

E. Marchioni, P. Ferrante, F. Rodeghiero, 2009, Annals of Hematology.

Successful pregnancy in a woman with congenital factor XIII deficiency treated with substitutive therapy

F. Rodeghiero, G. Castaman, M. Ruggeri, 1987, Blut.

ETRO Working Party on Factor XIII Questionnaire on Congenital Factor XIII Deficiency in Europe: Status and Perspectives

F. Rodeghiero, R. Seitz, S. Lopaciuk, 1996, Seminars in thrombosis and hemostasis.

A study on mutual interaction between cytokine induced killer cells and umbilical cord-derived mesenchymal cells: Implication for their in-vivo use.

F. Rodeghiero, K. Chieregato, G. Astori, 2012, Blood cells, molecules & diseases.

Further evidence of heterogeneity of gene defects in Italian families with factor XIII deficiency

M. Morfini, F. Rodeghiero, G. Castaman, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

A (15;17) translocation not associated with acute promyelocytic leukaemia

F. Rodeghiero, A. Biondi, E. di Bona, 1996, British journal of haematology.

Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria.

T. Barbui, G. Barosi, A. Vannucchi, 2010, Blood.

Treatment of von Willebrand disease.

F. Rodeghiero, G. Castaman, 2005, Seminars in hematology.

MCMDM-1VWD study diagnosed with type 1 von Willebrand disease in the European variant in a patient 12 Identification and characterization of a novel P2Y

S. Watson, F. Rodeghiero, A. Mumford, 2012 .

MCMDM-1 VWD study diagnosed with type 1 von Willebrand disease in the European variant in a patient 12 Identification and characterization of a novel P 2 Y

S. Watson, F. Rodeghiero, A. Mumford, 2009 .

Identification and characterization of a novel P 2 Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1 VWD study

S. Mundell, S. Watson, F. Rodeghiero, 2009 .

Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia

T. Barbui, P. Mannucci, F. Rodeghiero, 1984 .

Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia.

T. Barbui, P. Mannucci, F. Rodeghiero, 1984, Blood.

Immune thrombocytopenia in myeloid and lymphoid clonal disorders: an intriguing association

F. Rodeghiero, 2021, Haematologica.

Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia.

F. Rodeghiero, G. Castaman, E. Dini, 1990, Haematologica.

Evaluation of non-relapse mortality risk in hematopoietic stem cell transplantation; usefulness of the pretransplant scoring systems

A. Tosetto, F. Rodeghiero, C. Borghero, 2014 .

Spectrum of mutations in Albanian patients with haemophilia A: identification of ten novel mutations in the factor VIII gene

F. Rodeghiero, G. Castaman, S. Giacomelli, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

C ombined MV-trans Retinoic Acid and Idarubicin (AIDA) Therapy

T. Barbui, F. Mandelli, G. Avvisati, 1997 .

Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice

R. Fanin, G. Pizzolo, I. Nichele, 2013, American journal of hematology.

The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high‐risk patients with chronic lymphocytic leukemia

F. Rodeghiero, C. Visco, R. Sartori, 2013, American journal of hematology.

Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers

F. Ferrara, D. Caramazza, M. Nichelatti, 2018, American journal of hematology.

The Coagulopathy of Acute Leukemia

F. Rodeghiero, G. Castaman, 1992 .

Acquired plasma factor XIII deficiencies.

A. Tosetto, F. Rodeghiero, G. Castaman, 1993, Haematologica.

Multicenter Italian Study on Subcutaneous Concentrated Desmopressin (Emosint) for the in-Hospital and Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A: Outline of the Project

F. Rodeghiero, G. Castaman, 1993 .

Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance

A. Tosetto, F. Rodeghiero, G. Castaman, 2009, Journal of thrombosis and haemostasis : JTH.

Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.

T. Barbui, F. Mandelli, G. Avvisati, 1997, Blood.

Fibrinopeptide A changes during remission induction treatment with L-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation.

F. Rodeghiero, G. Castaman, E. Dini, 1990, Thrombosis research.

Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia – very long follow‐up

A. Rohatiner, T. Barbui, J. Fitzgibbon, 2014, British journal of haematology.

The management of ‘low‐risk’ and ‘intermediate‐risk’ patients with primary thrombocythaemia

T. Barbui, A. Tosetto, F. Rodeghiero, 1999, British journal of haematology.

Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor

P. Mannucci, J. Eikenboom, R. Montgomery, 2006, Journal of thrombosis and haemostasis : JTH.

Current Management of von Willebrand’s Disease

F. Rodeghiero, G. Castaman, 1995, Drugs.

Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patients

P. Mannucci, A. Tosetto, F. Rodeghiero, 2012, Journal of thrombosis and haemostasis : JTH.

Pregnancy and delivery in women with von Willebrand’s disease and different von Willebrand factor mutations

A. Tosetto, F. Rodeghiero, G. Castaman, 2010, Haematologica.

Bleeding scores in inherited bleeding disorders: clinical or research tools?

A. Tosetto, F. Rodeghiero, G. Castaman, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach.

A. Tosetto, F. Rodeghiero, G. Castaman, 2008, Blood.

A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD)

A. Tosetto, J. Goudemand, S. Lethagen, 2006, Journal of thrombosis and haemostasis : JTH.

The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study

A. Tosetto, S. Lethagen, J. Eikenboom, 2005, Journal of thrombosis and haemostasis : JTH.

von Willebrand's disease and hemophilia A Consistency of responses to repeated DDAVP infusions in patients with

F. Rodeghiero, G. Castaman, M. Ruggeri, 2011 .

Clinical Efficacy of Desmopressin and Consistency of Responses to Separate Infusion in Patients with Prolonged Bleeding time Due to Congenital Platelet Defect

F. Rodeghiero, Giancarlo Castman, G. Castman, 1993 .

Impact, Diagnosis and Treatment of von Willebrand Disease

P. Mannucci, D. Ginsburg, F. Rodeghiero, 2000, Thrombosis and Haemostasis.

Management of menorrhagia in women with inherited bleeding disorders: general principles and use of desmopressin

F. Rodeghiero, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Platelet von willebrand factor abnormalities in myeloproliferative syndromes

P. Mannucci, A. Tosetto, F. Rodeghiero, 1995, American journal of hematology.

Clinical significance of fibrinopeptide A in acute lymphocytic and non-lymphocytic leukaemia

F. Rodeghiero, G. Castaman, S. Castronovo, 1989, Blut.

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

T. Barbui, F. Rodeghiero, G. Finazzi, 1995, The New England journal of medicine.

Introduction to a review series on the treatment of thrombocytopenic disorders: something old, something new

F. Rodeghiero, 2022, Haematologica.

Congenital afibrinogenemia: Successful prevention of recurrent hemoperitoneum during ovulation by oral contraceptive

F. Rodeghiero, G. Castaman, M. Ruggeri, 1995, American journal of hematology.

Hepatitis B vaccination of 113 hemophiliacs: Lower antibody response in anti‐LAV/HTLV‐III‐positive patients

A. Zanetti, E. Tanzi, A. Zanetti, 1986, American journal of hematology.

Molecular mechanisms of type II factor XIII deficiency: novel Gly562-Arg mutation and C-terminal truncation of the A subunit cause factor XIII deficiency as characterized in a mammalian expression system.

F. Rodeghiero, G. Castaman, H. Umeyama, 1998, Blood.

Epidemiology of von Willebrand disease in developing countries.

F. Rodeghiero, A. Srivastava, 2005, Seminars in thrombosis and hemostasis.

Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.

Francesco Rodeghiero, P. Mannucci, F. Rodeghiero, 2003, Haematologica.

Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial.

P. Mannucci, F. Rodeghiero, G. Castaman, 1992, Blood.

Pregnancy and delivery in patients with homozygous or heterozygous R854Q type 2N von Willebrand disease

F. Rodeghiero, G. Castaman, M. Bernardi, 2005, Journal of thrombosis and haemostasis : JTH.

First Italian families with homozygous R854Q type 2 N von Willebrand disease.

F. Rodeghiero, G. Castaman, L. Contino, 2002, Thrombosis and haemostasis.

Deep intronic variations may cause mild hemophilia A

E. Santagostino, F. Rodeghiero, G. Castaman, 2011, Journal of thrombosis and haemostasis : JTH.

Disseminated intravascular coagulation after infusion of FEIBA (factor VIII inhibitor bypassing activity) in a patient with acquired haemophilia.

F. Rodeghiero, S. Castronovo, E. Dini, 1982, Thrombosis and haemostasis.

NON-A, NON-B HEPATITIS AFTER FACTOR VIII CONCENTRATE TREATED BY HEATING AND CHLOROFORM

F. Rodeghiero, P. Mannucci, M. Colombo, 1985, The Lancet.

F8 mRNA studies in haemophilia A patients with different splice site mutations

E. Santagostino, F. Rodeghiero, G. Castaman, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Fifth Åland Island conference on von Willebrand disease

M. Blombäck, P. T. Onundarson, P. Mannucci, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Von Willebrand Disease: Epidemiology

F. Rodeghiero, G. Castaman, 2007 .

Assessing bleeding in von Willebrand disease with bleeding score.

A. Tosetto, F. Rodeghiero, G. Castaman, 2007, Blood reviews.

Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H‐M740I) defect

F. Rodeghiero, G. Castaman, A. Federici, 2006, Journal of thrombosis and haemostasis : JTH.

[Prevention of hemorrhage and dental treatment of patients with congenital or acquired coagulopathies].

A. Tosetto, F. Rodeghiero, G. Castaman, 1997, Minerva stomatologica.

Treatment of hemophilia.

F. Rodeghiero, 1985, La Ricerca in clinica e in laboratorio.

F. Mandelli, G. Gaidano, F. Cottone, 2016, American journal of hematology.

Quantitative assessment of bleeding in haemorrhagic disorders : the case of menorrhagia

A. Tosetto, P. James, F. Rodeghiero, 2008 .

Theraw with Virus-= I I Inactivated Plasma Concentrates

P. Mannucci, F. Rodeghiero, G. Castaman, 2009 .

A novel fibrinogen gamma chain mutation (gamma 239 Gln-->His) is the cause of dysfibrinogenemia Vicenza.

S. Duga, F. Rodeghiero, G. Castaman, 2005, Journal of thrombosis and haemostasis : JTH.

Clinical effectiveness of desmopressin in a case of acquired von Willebrand's syndrome associated with benign monoclonal gammopathy

F. Rodeghiero, G. Castaman, M. Ruggeri, 1989, Blut.

Desmopressin‐induced thrombocytopenia in type i platelet discordant von willebrand disease

P. Mannucci, F. Rodeghiero, G. Castaman, 1993, American journal of hematology.

Management of Spontaneous Bleeding and Prevention of Bleeding After Dental Extractions and Other Surgical Procedures in Mild Hemophilia a and Von Willebrand’s Disease: Ten Years of Experience at the Vicenza Hemophilia and Thrombosis Center

F. Rodeghiero, G. Castaman, M. Ruggeri, 1993 .

Effectiveness of high‐dose intravenous immunoglobulin in a case of acquired von willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate

A. Tosetto, F. Rodeghiero, G. Castaman, 1992, American journal of hematology.

Von Willebrand Factor Antigen Is Less Sensitive than Ristocetin Cofactor for the Diagnosis of Type I von Willebrand Disease -Results Based on an Epidemiological Investigation

A. Tosetto, F. Rodeghiero, G. Castaman, 1990, Thrombosis and Haemostasis.

Pregnancy in Women with Type 1 von Willebrand Disease Caused by Heterozygosity for von Willebrand Factor Mutation C1130F

J. Eikenboom, F. Rodeghiero, G. Castaman, 2000, Thrombosis and Haemostasis.

Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation

A. Tosetto, J. Eikenboom, F. Rodeghiero, 2011, Journal of thrombosis and haemostasis : JTH.

The Epidemiology of von Willebrand Disease

F. Rodeghiero, G. Castaman, 2011 .

The impact of bleeding history, von Willebrand factor and PFA–100® on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM‐1VWD

A. Tosetto, J. Goudemand, S. Lethagen, 2010, British journal of haematology.

International consensus report on the investigation and management of primary immune thrombocytopenia.

Drew Provan, Robert McMillan, Shirley Watson, 2010, Blood.

Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1VWD)

A. Tosetto, J. Goudemand, S. Lethagen, 2007, Journal of thrombosis and haemostasis : JTH.

Von Willebrand Disease: Clinical Aspects and Practical Management

A. Tosetto, F. Rodeghiero, G. Castaman, 2014 .

A comparison between two semi‐quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease

A. Tosetto, J. Goudemand, S. Lethagen, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

A Standard Nomenclature for von Willebrand Factor Gene Mutations and Polymorphisms

J. Eikenboom, D. Ginsburg, F. Rodeghiero, 2001, Thrombosis and Haemostasis.

Laboratory issues in bleeding disorders

F. Rodeghiero, A. Ruiz-Sáez, C. Hayward, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Prevalence and diagnosis of haemorrhagic disorders and evaluation of effectiveness of WFH laboratory training workshops in Latin America

F. Rodeghiero, A. Ruiz-Sáez, C. Hayward, 2008 .

A new variant of von Willebrand disease (type II I) with a normal degree of proteolytic cleavage of von Willebrand factor.

P. Mannucci, F. Rodeghiero, G. Castaman, 1992, Thrombosis research.

First factor IX mutations in Albanian hemophilia B patients

F. Rodeghiero, G. Castaman, S. Giacomelli, 2008, American journal of hematology.

Failure of repeated courses of high-dose intravenous immunoglobulin to induce stable remission in patients with chronic idiopathic thrombocytopenic purpura

F. Rodeghiero, M. Ruggeri, C. Schiavotto, 1995, Annals of Hematology.

From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use

J. Esteve, D. Colomer, T. Barbui, 2000 .

Systematically missing confounders in individual participant data meta-analysis of observational cohort studies

H Tunstall-Pedoe, Dan Jackson, S G Thompson, 2009, Statistics in medicine.

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.

D. Consonni, A. Zanella, G. Gaidano, 2014, Blood.

Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia

T. Barbui, A. Vannucchi, F. Passamonti, 2012, American journal of hematology.

Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature.

F. Rodeghiero, M. Ruggeri, C. Schiavotto, 1993, Haematologica.

Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group

H. Tamary, F. Rodeghiero, R. Wu, 2011, Haematologica.

Juvenile essential thrombocythemia: really a benign disease?

F. Rodeghiero, G. Castaman, E. Dini, 1989, Haematologica.

First Italian family with abnormal antithrombin III (an-III vicenza).

T. Barbui, F. Rodeghiero, 1981, Haematologica.

Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glul02Lys) in the second EGF‐like domain

M. Pinotti, F. Bernardi, M. Pinotti, 1995, British journal of haematology.

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

T. Brümmendorf, M. Baccarani, H. Kantarjian, 2004, Blood.

The European Hematology Association Roadmap for European Hematology Research: a consensus document.

G. Salles, B. Coiffier, H. Döhner, 2016, Haematologica.

Polycythemia vera and essential thrombocythemia in young patients.

F. Rodeghiero, G. Castaman, M. Ruggeri, 1993, Haematologica.

Prevalence and risk factors of non‐fatal venous thromboembolism in the active population of the VITA Project

A. Tosetto, F. Rodeghiero, M. Frezzato, 2003, Journal of thrombosis and haemostasis : JTH.

Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults.

S. Tognazzo, D. Gemmati, F. Rodeghiero, 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

B‐cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities

A. Neri, I. Nichele, F. Maura, 2014, Hematological oncology.

In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.

T. Barbui, A. Vannucchi, F. Passamonti, 2014, Blood.

First-line Idiopathic Thrombocytopenic Purpura Therapies – Benefits and Limitations

F. Rodeghiero, M. Ruggeri, 2007 .

Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs.

T. Barbui, G. Rossi, F. Rodeghiero, 1997, Leukemia & lymphoma.

Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients

T. Barbui, G. Rossi, F. Rodeghiero, 2005, Leukemia & lymphoma.

Thrombosis associated with angiogenesis inhibitors.

A. Falanga, F. Rodeghiero, F. Elice, 2009, Best practice & research. Clinical haematology.

A follow-up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high-dose immunoglobulins and anti-D immunoglobulins.

F. Rodeghiero, G. Castaman, M. Ruggeri, 1992, Haematologica.

Fulminant sepsis in adults splenectomized for idiopathic thrombocytopenic purpura.

F. Rodeghiero, G. Castaman, E. Dini, 1992, Haematologica.

Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia

J. Viallard, F. Rodeghiero, A. Salama, 2018, Journal of hematology.

Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.

F. Rodeghiero, G. Castaman, 1993, Haematologica.

Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B-cell/L3 acute leukemia and advanced-stage Burkitt's lymphoma.

T. Barbui, A. Rossi, F. Rodeghiero, 1996, Haematologica.

Erythroleukaemia, diabetes insipidus and hypophyseal damage: Two case reports.

A. Piccin, F. Rodeghiero, R. Raimondi, 2007, Leukemia research.

Brief communication Erythroleukaemia, diabetes insipidus and hypophyseal damage: Two case reports

A. Piccin, F. Rodeghiero, R. Raimondi, 2007 .

Absence of micronucleus formation in CHO-K1 cells cultivated in platelet lysate enriched medium.

F. Rodeghiero, V. Adami, G. Astori, 2014, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

Congenital absence of the inferior vena cava: a rare risk factor for idiopathic deep-vein thrombosis

A. Tosetto, F. Rodeghiero, G. Castaman, 2001, The Lancet.

Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia

B. Chong, F. Rodeghiero, J. Franklin, 2016, Annals of Hematology.

Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment‐related risk factors

G. Gaidano, A. Tosetto, V. De Stefano, 2014, Journal of thrombosis and haemostasis : JTH.

ITP and international guidelines: what do we know, what do we need?

F. Rodeghiero, M. Ruggeri, 2014, Presse medicale.

Real-world use of thrombopoietin receptor agonists in elderly patients with primary immune thrombocytopenia.

A. Patriarca, V. De Stefano, U. Consoli, 2021, Blood.

Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group.

J. Bussel, V. Blanchette, D. Cines, 2013, Blood.

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study.

F. Passamonti, M. Merli, F. Rodeghiero, 2019, Blood.

An acquired hemorrhagic disorder of fibrin crosslinking due to LgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide

A. Tosetto, F. Rodeghiero, C. Manotti, 1995, American journal of hematology.

Failure to measure plasma activated factor XIII during disseminated intravascular coagulation

T. Barbui, F. Rodeghiero, M. Morbin, 1981, La Ricerca in clinica e in laboratorio.

Fibrin cross-linking in congenital factor XIII deficiency.

T. Barbui, F. Rodeghiero, 1980, Journal of clinical pathology.

Molecular Subunits and Transamidase Activity of Factor XIII During Disseminated Intravascular Coagulation in Acute Leukaemia

T. Barbui, T. Chisesi, F. Rodeghiero, 1980, Thrombosis and Haemostasis.

Increased proteolysis of antithrombin III Vicenza during disseminated intravascular coagulation in acute leukemia.

F. Rodeghiero, G. Castaman, M. Ruggeri, 1989, Thrombosis research.

Intrinsic and method-induced variation of the bleeding time and related parameters

T. Barbui, F. Rodeghiero, G. Castaman, 2007 .

Hereditary Dysfunctional Antithrombin III (AT-III Vicenza)

T. Barbui, F. Rodeghiero, 1981, Thrombosis and Haemostasis.

Early haemorrhagic morbidity and mortality during remission induction with or without all‐trans retinoic acid in acute promyelocytic leukaemia

F. Mandelli, G. Avvisati, F. Rodeghiero, 2000, British journal of haematology.

Platelet von Willebrand factor assay: results using two methods for platelet lysis.

P. Mannucci, A. Tosetto, F. Rodeghiero, 1990, Thrombosis research.

Triton X contaminating platelet lysate critically affects the measurement of von Willebrand factor ristocetin cofactor activity.

A. Tosetto, F. Rodeghiero, G. Castaman, 1989, Thrombosis research.

Characterization of two cases of acquired transitory von willebrand syndrome with ciprofloxacin: Evidence for heightened proteolysis of von willebrand factor

P. Mannucci, F. Rodeghiero, G. Castaman, 1995, American journal of hematology.

Hemostatic complications of angiogenesis inhibitors in cancer patients

A. Falanga, F. Rodeghiero, F. Elice, 2008, American journal of hematology.

ABO-incompatible bone marrow transplantation: a GITMO survey of current practice in Italy and comparison with the literature

F. Rodeghiero, T. Lamparelli, A. Bacigalupo, 2004, Bone Marrow Transplantation.

Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy

T. Barbui, F. Mandelli, G. Avvisati, 1997 .

Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome

F. Rodeghiero, C. Visco, A. Ambrosetti, 2016, Annals of Hematology.

Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia.

G. Pizzolo, F. Rodeghiero, C. Visco, 2008, Blood.

lymphocytic leukemia Impact of immune thrombocytopenia on the clinical course of chronic

G. Pizzolo, F. Rodeghiero, C. Visco, 2008 .

Prolonged overall survival with second on‐demand autologous transplant in multiple myeloma

A. Piccin, A. Tosetto, F. Rodeghiero, 2006, American journal of hematology.

Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols

M. Gobbi, R. Fanin, M. Vignetti, 2003, Leukemia.

Management of immune thrombocytopenia in women: current standards and special considerations

F. Rodeghiero, Ettore Marranconi, 2020, Expert review of hematology.

The Epidemiology of lnherited Thrombophilia: the VITA Project

A. Tosetto, F. Rodeghiero, 1997, Thrombosis and Haemostasis.

The VITA Project: Population-based Distributions of Protein C, Antithrombin III, Heparin-cofactor II and Plasminogen -Relationship with Physiological Variables and Establishment of Reference Ranges

A. Tosetto, F. Rodeghiero, 1996, Thrombosis and Haemostasis.

Activated Protein C Resistance and Factor V Leiden Mutation Are Independent Risk Factors for Venous Thromboembolism

A. Tosetto, F. Rodeghiero, 1999, Annals of Internal Medicine.

Heterogeneity of Activated Protein C Resistance Phenotype in Subjects with Compound Heterozygosity for HR2 Haplotype and FV Leiden Mutation (R506Q) in Factor V Gene

A. Tosetto, F. Rodeghiero, G. Castaman, 2000, Thrombosis and Haemostasis.

Two families with combined homozygous/heterozygous factor V Leiden mutation and heterozygous G20210A factor II variant.

A. Tosetto, F. Rodeghiero, G. Castaman, 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Calibration of Lyophilized Standards for Ristocetin Cofactor Activity of von Willebrand Factor (vWF) Requires vWF-Deficient Plasma as Diluent for Dose-Response Curves

F. Rodeghiero, G. Castaman, 1987, Thrombosis and Haemostasis.

Fibrinolytic studies in 13 unrelated families with factor XII deficiency.

F. Rodeghiero, G. Castaman, M. Ruggeri, 1991, Haematologica.

Mobilization and collection of PBSC in healthy donors: a retrospective analysis of the Italian Bone Marrow Transplantation Group (GITMO).

F Locatelli, F Rodeghiero, T. Barbui, 1997, Haematologica.

Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene

S. Fortuna, F. Rodeghiero, M. Ruggeri, 2012, Haematologica.

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.

A. Zanella, L. Luzzatto, A. Risitano, 2009, Blood.

A new TMHA‐DHPLC assay for the rapid mutation screening of JAK2 exon 14 in myeloproliferative disorders

F. Rodeghiero, M. Ruggeri, E. Albiero, 2008, American journal of hematology/oncology.

Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies

B. Chong, F. Rodeghiero, I. Pabinger, 2019, British journal of haematology.

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia

M. Steurer, D. Cines, B. Chong, 2017, Haematologica.

Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes.

F Rodeghiero, G. Pizzolo, S. Ferrini, 1997, Blood.

Paroxysmal nocturnal hemoglobinuria (PNH) in the eculizumab era: The bedside and beyond.

A. Zanella, L. Luzzatto, F. Rodeghiero, 2008 .

Low Prevalence of JAK2 Val617Phe Mutation in Patients with Idiopathic Erythrocytosis.

T. Barbui, F. Rodeghiero, A. Rambaldi, 2005 .

The Rate of Progression to Polycythemia Vera or Essential Thrombocythemia in Patients with Erythrocytosis or Thrombocytosis

A. Tosetto, F. Rodeghiero, M. Ruggeri, 2003, Annals of Internal Medicine.

Analysis of the oxygen sensing pathway genes in familial chronic myeloproliferative neoplasms and identification of a novel EGLN1 germ‐line mutation

S. Fortuna, F. Rodeghiero, M. Ruggeri, 2011, British journal of haematology.

Inhibitor development: The last enemy to be defeated in hemophilia A and B

F. Rodeghiero, G. Castaman, 2014, American journal of hematology.

ERYTHROCYTE FRAGMENTATION IN DISSEMINATED INTRAVASCULAR COAGULATION (DIC) IN ACUTE LEUKAEMIA

F. Rodeghiero, G. Castaman, Enrico Dini, 1985, British journal of haematology.

Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia

F. Rodeghiero, B. Godeau, D. Kuter, 2020, Expert review of hematology.

Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study.

R. Fanin, A. Bosi, A. Tosetto, 2012, Blood.

Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: A critical appraisal from literature analysis

S. Fortuna, F. Rodeghiero, M. Ruggeri, 2006, Pediatric blood & cancer.

Idiopathic thrombocytopenic purpura in regnancy

F. Rodeghiero, M. Ruggeri, 2009 .

Results From a Phase IV Open-Label Study Evaluating Changes In Bone Marrow Morphology In Adult Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim: Analysis Of The 1- and 2-Year Romiplostim Cohorts

B. Chong, F. Rodeghiero, I. Pabinger, 2013 .

Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases,

J. Bussel, C. Kessler, F. Rodeghiero, 2011 .

The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.

B. Chong, F. Rodeghiero, I. Pabinger, 2010 .

A comparative prospective observational study of children and adults with immune thrombocytopenia: 2‐year follow‐up

H. Tamary, F. Rodeghiero, R. Wu, 2018, American journal of hematology.

Safety and efficacy of self‐administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials

F. Rodeghiero, A. Newland, D. Kuter, 2020, American journal of hematology.

Final Results from a Phase 4 Open-Label 3-Year Study Evaluating Changes in Bone Marrow (Bm) Morphology in Adult Immune Thrombocytopenia (ITP) Patients (Pts) Receiving the Thrombopoietin Mimetic Romiplostim

B. Chong, F. Rodeghiero, I. Pabinger, 2014 .

ITP and thrombosis: an intriguing association.

F. Rodeghiero, 2017, Blood advances.

Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy

C. Santoro, U. Consoli, F. Rodeghiero, 2023, Mediterranean journal of hematology and infectious diseases.

Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy.

M. Chilosi, G. Pizzolo, M. Merli, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-lasting remission after high-dose intravenous immunoglobulins in a case of relapsing thrombotic thrombocytopenic purpura.

F. Rodeghiero, G. Castaman, M. Ruggeri, 1991, Haematologica.

Low‐dose alemtuzumab‐associated immune thrombocytopenia in chronic lymphocytic leukemia

F. Maura, A. Cortelezzi, F. Rodeghiero, 2012, American journal of hematology.

Adult patients with the nephrotic syndrome: really at high risk for deep venous thromboembolism? Report of a series and review of the literature.

F Rodeghiero, F. Rodeghiero, G. Castaman, 1993, Haematologica.

Recurrence of the ‘deep-intronic’ FGG IVS6-320A>T mutation causing quantitative fibrinogen deficiency in the Italian population of Veneto

S. Duga, M. Platé, F. Rodeghiero, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Autoimmune cytopenias in chronic lymphocytic leukemia

A. Neri, F. Maura, A. Cortelezzi, 2014, American journal of hematology.

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

T. Barbui, A. Vannucchi, F. Passamonti, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alterations of mRNA processing and stability as a pathogenic mechanism in von Willebrand factor quantitative deficiencies

S. Duga, M. Platé, F. Rodeghiero, 2010, Journal of thrombosis and haemostasis : JTH.

Practical Recommendations for the Management of Patients with ITP During the COVID-19 Pandemic

V. De Stefano, C. Santoro, F. Rodeghiero, 2021, Mediterranean journal of hematology and infectious diseases.

The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines.

F. Rodeghiero, C. Visco, K. Chieregato, 2012, Blood cells, molecules & diseases.

Subunits A and S Inheritance in Four Families with Congenital Factor XIII Deficiency

T. Barbui, G. Mariani, F. Rodeghiero, 1978, British journal of haematology.

Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).

T. Barbui, A. Vannucchi, F. Passamonti, 2012, Blood.

No Influence of Blood Group on the Responsiveness to Desmopressin in Type I “Platelet Normal” von Willebrand’s Disease

F. Rodeghiero, G. Castaman, 1995, Thrombosis and Haemostasis.

Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors

L. Baldini, A. Neri, L. Agnelli, 2011, Clinical Cancer Research.

B-cell Receptors Lymphocytic Leukemia Is Associated with Stereotyped Immune Thrombocytopenia in Patients with Chronic Updated

L. Baldini, A. Neri, L. Agnelli, 2012 .

Hematologic malignancies and thrombosis.

F. Rodeghiero, F. Elice, 2012, Thrombosis research.

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies.

F. Rodeghiero, G. Castaman, L. Trentin, 1997, Haematologica.

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.

M. Cazzola, C. Pascutto, T. Barbui, 2012, Blood.

The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting

C. Patrono, A. Vannucchi, A. Tosetto, 2018, Blood Cancer Journal.

B‐cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia

R. Foà, A. Neri, V. Callea, 2012, American journal of hematology.

Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.

G. Pizzolo, F. Rodeghiero, C. Visco, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Heterogeneity of Specific CD4+ and CD8+ T Cells Stimulated by CMV pp65 and IE1 Antigens

H. Einsele, F. Rodeghiero, G. Grigoleit, 2016, Journal of immunotherapy.

Heightened proteolysis of the von Willebrand factor subunit in patients with von Willebrand disease hemizygous or homozygous for the C2362F mutation

P. Mannucci, J. Eikenboom, F. Rodeghiero, 2000, British journal of haematology.

An Additional Unique Candidate Mutation (G2470A; M740I) in the Original Families with von Willebrand Disease Type 2 M Vicenza and the G3864A (R1205H) Mutation

E. Missiaglia, F. Rodeghiero, G. Castaman, 2000, Thrombosis and Haemostasis.

Autosomal Recessive von Willebrand Disease Type 1 or 2 due to Homozygous or Compound Heterozygous Mutations in the von Willebrand Factor Gene

F. Rodeghiero, G. Castaman, S. Giacomelli, 2009, Acta Haematologica.

Fibrinogen assays: a collaborative study of six different methods. C.I.S.M.E.L. Comitato Italiano per la Standardizzazione dei Metodi in Ematologia e Laboratorio.

P. Mannucci, G. Palareti, F. Rodeghiero, 1991, Clinical chemistry.

M. Vignetti, G. Avvisati, F. Lo Coco, 2018, Leukemia.

Consistency of responses to separate desmopressin infusions in patients with storage pool disease and isolated prolonged bleeding time.

F. Rodeghiero, G. Castaman, 1993, Thrombosis research.

Acquired transitory von Willebrand syndrome with ciprofloxacin

F. Rodeghiero, G. Castaman, 1994, The Lancet.

Topologically equivalent mutations causing dysfunctional coagulation factors VII (294Ala-->Val) and X (334Ser-->Pro).

M. Pinotti, F. Bernardi, M. Pinotti, 1994, Human molecular genetics.

PREGNANCY IN WOMEN WITH ESSENTIAL THROMBOCYTHAEMIA

F. Rodeghiero, O. Shpilberg, I. Ben-bassat, 1996, British journal of haematology.

Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis.

T. Barbui, F. Rodeghiero, G. Finazzi, 2003, Blood.

Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.

T. Barbui, A. Vannucchi, F. Passamonti, 2012, Blood.

Recurrent thrombosis in patients with polycythemia vera or essential thrombocythemia : efficacy of treatment in preventing rethrombosis in different clinical settings

T. Barbui, G. Leone, A. Vannucchi, 2006 .

Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO‐criteria and stratified by calendar period of diagnosis

T. Barbui, A. Vannucchi, F. Passamonti, 2015, American journal of hematology.

Comorbidity Index: a prospective, multicenter GITMO study Validation of the Hematopoietic Cell Transplantation-Specific

R. Fanin, A. Bosi, A. Tosetto, 2012 .

The VITA Project: Heritability of Resistance to Activated Protein C

A. Tosetto, F. Rodeghiero, G. Castaman, 2000, Thrombosis and Haemostasis.

Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.

T. Barbui, P. Guglielmelli, A. Vannucchi, 2008, Blood.

Prognostic significance of CD56 antigen expression in acute myeloid leukemia.

F. Rodeghiero, R. Sartori, R. Zambello, 2002, Haematologica.

Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper

T. Barbui, G. Barosi, A. Vannucchi, 2019, Blood Cancer Journal.

Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use

F. Rodeghiero, M. Ruggeri, O. Perbellini, 2017, Stem Cell Research & Therapy.

Survival and Risk of Leukemic transformation in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study on 1,104 Patients

T. Barbui, A. Vannucchi, F. Passamonti, 2010 .

DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma

R. Cairoli, E. Morra, F. Rodeghiero, 2001, Bone Marrow Transplantation.

Effect of DCEP Mobilizing Regimen in in vivo Purging of PBSC Harvests in Multiple Myeloma

F. Rodeghiero, G. Castaman, F. Elice, 2004, Leukemia & lymphoma.

Targeting the Endothelium in Cancer : Clinical Implications

F. Rodeghiero, F. Elice, 2003 .

Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.

T. Barbui, F. Rodeghiero, F. Elice, 2004, Haematologica.

An Reduced Plasma Membrane Ca 2+ -atpase Function in Platelets from Patients with Non-insulin-dependent Diabetes Mellitus Letters to the Editor

T. Barbui, F. Rodeghiero, F. Elice, 2022 .

treated by eculizumab patients mechanism of disease in paroxysmal nocturnal hemoglobinuria Complement fraction 3 binding on erythrocytes as additional

L. Luzzatto, A. Risitano, F. Rodeghiero, 2013 .

Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.

T. Barbui, F. Rodeghiero, R. Bassan, 1998, Haematologica.

A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

M. Cazzola, C. Pascutto, T. Barbui, 2011 .

Recent progress in ITP treatment

F. Rodeghiero, 2023, International Journal of Hematology.

Histidine-rich glycoprotein changes during pregnancy in a woman with genetically transmitted high levels of the protein and thrombotic diathesis.

F. Rodeghiero, G. Castaman, M. Ruggeri, 1993, Thrombosis research.

Association of Platelet Thromboxane Inhibition by Low‐Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia

C. Patrono, A. Vannucchi, A. Tosetto, 2021, Clinical pharmacology and therapeutics.

Fibrin glue from single‐donation autologous plasmapheresis

A. Tosetto, F. Rodeghiero, P. Rivasi, 1992, Transfusion.

Fibrinogen Vicenza and Genova II: Two New Cases of Congenital Dysfibrinogenemia with Isolated Defect of Fibrin Monomer Polymerization and Inhibitory Activity on Normal Coagulation

F. Rodeghiero, G. Castaman, A. Peruffo, 1987, Thrombosis and Haemostasis.

A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.

C. Patrono, A. Vannucchi, A. Tosetto, 2020, Blood.

Intraindividual consistency of the activated protein C resistance phenotype

A. Tosetto, F. Rodeghiero, D. Madeo, 2004, British journal of haematology.

Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status

F. Rodeghiero, C. Visco, R. Paolini, 2010, Haematologica.

Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia

A. Tosetto, F. Rodeghiero, C. Visco, 2007, Leukemia.

Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD.

A. Tosetto, J. Goudemand, S. Lethagen, 2010, Thrombosis research.

Homocysteine levels in polycythaemia vera and essential thrombocythaemia

H. Gisslinger, C. Mannhalter, F. Rodeghiero, 1999, British journal of haematology.

Association of plasma fibrinogen, C-reactive protein and G-455>A polymorphism with early atherosclerosis in the VITA Project cohort

P. Prati, R. Manara, A. Tosetto, 2010, Thrombosis and Haemostasis.

Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A

F. Rodeghiero, G. Castaman, M. Ruggeri, 1989 .

Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines

F. Rodeghiero, C. Visco, K. Chieregato, 2012, Leukemia & lymphoma.

Age‐adjusted reference limits for carotid intima‐media thickness as better indicator of vascular risk: population‐based estimates from the VITA project

P. Prati, R. Manara, A. Tosetto, 2005, Journal of thrombosis and haemostasis : JTH.

Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology

F. Rodeghiero, H. Al‐Samkari, R. Grace, 2021, Journal of thrombosis and haemostasis : JTH.

Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden

M. Vignetti, M. Luppi, F. Cottone, 2020, BMJ Supportive & Palliative Care.

Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia

L. Bonaldi, G. Pizzolo, M. Scupoli, 2014, Haematologica.

Clinical significance of LAIR 1 ( CD 305 ) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia

L. Bonaldi, G. Pizzolo, M. Scupoli, 2014 .

Failure of DDAVP to shorten the prolonged bleeding time of two patients with congenital afibrinogenemia.

F. Rodeghiero, G. Castaman, 1992, Thrombosis research.

Response:Immune thrombocytopenic purpura: terminology and definitions

F. Rodeghiero, M. Ruggeri, 2009 .

Flow cytometry in the diagnosis of drug‐induced thrombocytopenia: Two illustrative cases

F. Rodeghiero, G. Castaman, C. Visco, 2008, American journal of hematology.

Angiodysplasia and von Willebrand’s Disease

F. Rodeghiero, G. Castaman, E. di Bona, 1994, Thrombosis and Haemostasis.

The revival of clinical wisdom: The case of oral anticoagulation management

F. Rodeghiero, 2009, American journal of hematology/oncology.

Immunophenotypic and genotypic characterization of B-cell chronic lymphocytic leukemia patients from northern Italy.

F. Rodeghiero, G. Castaman, M. Ruggeri, 1993 .

Treatment outcome in a cohort of young patients with polycythemia vera

S. Fortuna, F. Rodeghiero, M. Ruggeri, 2010, Internal and emergency medicine.

Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion

V. De Stefano, F. Rodeghiero, N. Vianelli, 2023, Therapeutic Advances in Hematology.

Congenital hypofibrinogenemia associated with novel heterozygous fibrinogen Bβ and γ chain mutations

S. Duga, F. Rodeghiero, G. Castaman, 2008, Haemophilia.

Bβ 14 Arg→Cys variant dysfibrinogen and its association with thrombosis

A. Tosetto, F. Rodeghiero, G. Castaman, 2005, Journal of Thrombosis and Haemostasis.

Additional genetic risk factors for venous thromboembolismin carriers of the factor V Leiden mutation

P. Chiusolo, P. Mannucci, A. Tosetto, 1998, British journal of haematology.

Diagnosis of APC Resistance in Patients on Oral Anticoagulant Therapy

A. Tosetto, F. Rodeghiero, 1995, Thrombosis and Haemostasis.

Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

B. Chong, F. Rodeghiero, I. Pabinger, 2009 .

The bleeding time in normal subjects is mainly determined by platelet von Willebrand factor and is independent from blood group.

A. Tosetto, F. Rodeghiero, G. Castaman, 1992, Thrombosis research.

The Genetic Defect of Type I von Willebrand Disease “Vicenza” Is Linked to the von Willebrand Factor Gene

E. Sacchi, P. Mannucci, F. Rodeghiero, 1993, Thrombosis and Haemostasis.

Thrombotic risk in patients with immune haemolytic anaemia

F. Rodeghiero, M. Ruggeri, 2016, British journal of haematology.

The clinical significance of the antiplatelet antibody test based on results for 265 thrombocytopenic patients.

A. Tosetto, F. Rodeghiero, M. Ruggeri, 1993, Haematologica.

Acquired transitory factor XI inhibitor after gynaecological surgery

F. Rodeghiero, G. Castaman, M. Ruggeri, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

The VITA Project: C677T mutation in the methylene‐tetrahydrofolate reductase gene and risk of venous thromboembolism

A. Tosetto, E. Missiaglia, F. Rodeghiero, 1997, British journal of haematology.

Hyperuricemic syndromes : pathophysiology and therapy

C. Ronco, F. Rodeghiero, 2004 .

The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia.

F. Rodeghiero, G. Castaman, 1994, Leukemia.

Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia.

T. Barbui, P. Mannucci, A. Falanga, 1993, Thrombosis research.

Defective Fibrin Crosslinking in Acute Leukemia

T. Barbui, F. Rodeghiero, E. Dini, 1984, Thrombosis and Haemostasis.

Platelet ristocetin cofactor (RiCof) in patients with type I "platelet normal" von Willebrand disease correlates with plasma RiCof peak after desmopressin infusion.

F. Rodeghiero, G. Castaman, 1995, Thrombosis research.

Fall Off of Factor VIII Elicited by Desmopressin Administration in Hemophiliacs and von Willebrand’s Disease Patients

M. Morfini, S. Cinotti, F. Rodeghiero, 1993 .

One Year Follow-Up Study of T-Cell Subsets and Incidence of Seropositivity for HTLV-I and HTLV-III Antibodies in Patients Treated “On Demand” or Sporadically with Clotting Concentrates

T. Chisesi, A. Del Mistro, L. Chieco‐Bianchi, 1985, Thrombosis and Haemostasis.

International survey on Helicobacter pylori testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee

Y. Tomiyama, F. Rodeghiero, T. Bakchoul, 2020, Journal of thrombosis and haemostasis : JTH.

High-dose dexamethasone in adult refractory idiopathic thrombocytopenic purpura.

F. Rodeghiero, G. Castaman, M. Ruggeri, 1996, British journal of haematology.

Pulmonary embolism after pregnancy in a patient with polycythemia vera

A. Tosetto, F. Rodeghiero, G. Castaman, 2001, American journal of hematology.

Fatal pulmonary embolism and antithrombin III deficiency in adult lymphoblastic leukaemia during L-asparaginase therapy.

T. Barbui, F. Rodeghiero, E. Dini, 1983, Acta haematologica.

(IPSET-thrombosis) essential thrombocythemia - thrombosis in World Health Organization Development and validation of an International Prognostic Score of

T. Barbui, F. Passamonti, A. Tefferi, 2013 .

Chapter 8. Von Willebrand Disease

F. Rodeghiero, G. Castaman, Alberto Tosetto and, 2010 .

FACTOR XIII SUBUNIT B DEFICIENCY

A. Tosetto, F. Rodeghiero, 1990, British journal of haematology.

P. Bartolomeo, M. Vignetti, F. Mandelli, 2016 .

A new Italian family with severe prekallikrein deficiency. Desmopressin-induced fibrinolysis and coagulation changes in homozygous and heterozygous members

F. Rodeghiero, G. Castaman, M. Ruggeri, 1990, La Ricerca in clinica e in laboratorio.

Thrombosis in Patients with Heterozygous and Homozygous Factor XII Deficiency Is not Explained by the Associated Presence of Factor V Leiden

A. Tosetto, E. Missiaglia, F. Rodeghiero, 1996, Thrombosis and Haemostasis.

Thrombosis in Subjects with Homozygous and Heterozygous Factor XII Deficiency

A. Tosetto, F. Rodeghiero, G. Castaman, 1992, Thrombosis and Haemostasis.

Severe factor XI deficiency in the Abruzzo region of Italy is associated to different FXI gene mutations

S. Duga, F. Rodeghiero, G. Castaman, 2008, Haematologica.

Factor XI gene mutations in factor XI deficient patients of the Czech Republic

S. Duga, F. Rodeghiero, G. Castaman, 2008, American journal of hematology.

Incidence and Determinants of Bleeding in Different Types of von Willebrand Disease: Results of the First Prospective Multicenter Study on 814 Italian Patients.

P. Mannucci, M. Morfini, P. Bucciarelli, 2007 .

Rituximab, Bendamustine and Cytarabine (R-BAC) Is a Very Active Regimen In Patients with Mantle Cell Lymphoma Not Eligible for Intensive Chemotherapy or Autologous Transplant

G. Pizzolo, G. Nadali, F. Rodeghiero, 2011 .

A novel heterozygous missense mutation (His127Arg) in a family with inherited cross-reacting material positive factor XI deficiency

F. Rodeghiero, G. Castaman, A. Tagliaferri, 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran

F. Rodeghiero, 2006, Internal and emergency medicine.

Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival

D. Rossi, G. Gaidano, K. Young, 2015, Oncotarget.

Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia.

F. Rodeghiero, M. Lozano, 2022, The Lancet. Haematology.

Acute renal failure after high-dose intravenous immune globulin in a patient with idiopathic thrombocytopenic purpura.

F. Rodeghiero, G. Castaman, M. Ruggeri, 1993, Haematologica.

The European Survey on Adult’s Evans Syndrome: Analysis of 54 Cases.

F. Rodeghiero, M. Michel, B. Godeau, 2005 .

Acquired haemophilia: experience of two Italian centres with 17 new cases

F. Rodeghiero, G. Castaman, N. Ciavarella, 1997, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Y. Miyakawa, J. Bussel, F. Rodeghiero, 2022, Blood.

Enumeration of residual white blood cells in leukoreduced blood products: Comparing flow cytometry with a portable microscopic cell counter.

F. Rodeghiero, K. Chieregato, A. Alghisi, 2016, Transfusion and Apheresis Science.

Gestational thrombocytopenia: a prospective study.

A. Tosetto, F. Rodeghiero, G. Castaman, 1997, Haematologica.

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

F. Ferrara, A. Cuneo, G. Pizzolo, 2006, Blood.

Blood group significantly influences von Willebrand factor increase and half‐life after desmopressin in von Willebrand disease Vicenza

A. Tosetto, J. Eikenboom, F. Rodeghiero, 2010, Journal of thrombosis and haemostasis : JTH.

Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: A EHA Consensus Report

P. Noris, A. Tosetto, F. Leebeek, 2019 .

Molecular characterization of five Italian families with inherited severe factor XIII deficiency

J. Oldenburg, F. Rodeghiero, G. Castaman, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Parallel line bioassay in a coagulation laboratory. A program for personal computer use and an example application to Ristocetin Cofactor assay.

A. Tosetto, F. Rodeghiero, 2008, Clinical and laboratory haematology.

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

F. Ferrara, A. Cuneo, G. Pizzolo, 2006, Blood.

Prevalence and prognostic impact of KIT mutations in acute myeloid leukaemia with inv(16). A retrospective study

G. Martinelli, F. Ferrara, A. Cuneo, 2007 .

A study on mutual interaction between cytokine induced killer cells and umbilical cord-derived mesenchymal cells: Implication for their in-vivo use.

F. Rodeghiero, K. Chieregato, G. Astori, 2012, Blood cells, molecules & diseases.

Identical IGHV‐D‐J gene rearrangement may precede the clinical onset of chronic lymphocytic leukemia by several years

F. Rodeghiero, D. Madeo, I. Giaretta, 2010, American journal of hematology.

C. Patrono, A. Vannucchi, A. Tosetto, 2018, Blood Cancer Journal.

Some Remarks on the Epidemiology of Thrombotic Disorders

A. Tosetto, F. Rodeghiero, 1993, Thrombosis and Haemostasis.

Autoimmune cytopenias in chronic lymphocytic leukemia

A. Neri, F. Maura, A. Cortelezzi, 2014, American journal of hematology.

Production of human platelet lysate by use of ultrasound for ex vivo expansion of human bone marrow-derived mesenchymal stromal cells.

F. Rodeghiero, K. Chieregato, A. Alghisi, 2013, Cytotherapy.

Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis.

J. Gallacher, J. Danesh, E. Rimm, 2012, International journal of epidemiology.

Symptomatic type II protein C deficiency caused by a missense mutation (Gly 381 → Ser) in the substrate‐binding pocket

A. Wacey, F. Bernardi, G. Marchetti, 1993, British journal of haematology.

B‐cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities

A. Neri, I. Nichele, F. Maura, 2014, Hematological oncology.

A novel heterozygous missense mutation (His127Arg) in a family with inherited cross-reacting material positive factor XI deficiency

F. Rodeghiero, G. Castaman, A. Tagliaferri, 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.

A. Zanella, L. Luzzatto, A. Risitano, 2009, Blood.

How I treat von Willebrand disease.

A. Tosetto, F. Rodeghiero, G. Castaman, 2009, Blood.

Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.

A. Tosetto, J. Goudemand, S. Lethagen, 2008, Blood.

Desmopressin and type II B von Willebrand disease

F. Rodeghiero, G. Castaman, 1996, Haemophilia.

Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD.

A. Tosetto, J. Batlle, F. Rodeghiero, 2010, Thrombosis research.

Pregnancy and delivery in women with von Willebrand’s disease and different von Willebrand factor mutations

A. Tosetto, F. Rodeghiero, G. Castaman, 2010, Haematologica.

A Prospective Evaluation of Bleeding Tendency and Efficacy of Antihemorrhagic Treatments in Patients with Increased Von Willebrand Factor (VWF) Clearance (Von Willebrand Disease Vicenza AND C1130F Mutation).

A. Tosetto, F. Rodeghiero, G. Castaman, 2008 .

Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach.

A. Tosetto, F. Rodeghiero, G. Castaman, 2008, Blood.

Chapter 6. Von Willebrand Disease

F. Rodeghiero, G. Castaman, A. T. and, 2007 .

Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol.

F. Rodeghiero, G. Castaman, C. Schiavotto, 1993, Haematologica.

Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia

T. Barbui, A. Vannucchi, F. Passamonti, 2012, American journal of hematology.

Effect of the VWF promoter (GT)n repeat and single‐nucleotide polymorphism c.‐2527G>A on circulating von Willebrand factor levels under normal conditions

D. Hampshire, F. Rodeghiero, A. Goodeve, 2011, Journal of Thrombosis and Haemostasis.

The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases.

J. Piette, E. Andrès, P. Bierling, 2009, Blood.

Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).

T. Barbui, A. Vannucchi, F. Passamonti, 2012, Blood.

VON WILLEBRAND FACTOR ABNORMALITIES IN TWO PATIENTS WITH URAEMIA

P. Mannucci, F. Rodeghiero, G. Castaman, 1988, The Lancet.

theorem approach Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes

A. Tosetto, F. Rodeghiero, G. Castaman, 2009 .

Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia

A. Neri, G. Pizzolo, M. Scupoli, 2013, American journal of hematology.

Deep intronic variations may cause mild hemophilia A

F. Rodeghiero, M. Mancuso, R. Santacroce, 2011, Journal of thrombosis and haemostasis : JTH.

Antibodies in Patients Treated liOn Demand" or Sporadically with Clotting Concentrates

T. Chisesi, A. Del Mistro, L. Chieco‐Bianchi, 2018 .

No treatment for low‐risk thrombocythaemia:results from a prospective study

Riva, T. Barbui, A. Tosetto, 1998, British journal of haematology.

Multivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine‐induced killer cells

F. Rodeghiero, M. Stocchero, K. Chieregato, 2013, Cytometry. Part B, Clinical cytometry.

Loss of the JAK2 intramolecular auto‐inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis

A. Giorgetti, F. Rodeghiero, M. Ruggeri, 2008, British journal of haematology.

In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.

T. Barbui, A. Vannucchi, F. Passamonti, 2014, Blood.